21573-09-1

Basic information

• Product Name: 2-aMino-4-chloro-6-cyclopropylpyriMidine
• Synonyms: 2-aMino-4-chloro-6-cyclopropylpyriMidine;4-chloro-6-cyclopropyl-pyriMidin-2-ylaMine
• CAS NO: 21573-09-1
• Molecular Formula: C₇H₈ClN₃
• Molecular Weight: 169.61152
• EINECS: -0
• Mol File: 21573-09-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-aMino-4-chloro-6-cyclopropylpyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-aMino-4-chloro-6-cyclopropylpyriMidine(21573-09-1)
• EPA Substance Registry System: 2-aMino-4-chloro-6-cyclopropylpyriMidine(21573-09-1)

Safety Data

• Hazardous Substances Data: 21573-09-1(Hazardous Substances Data)

Usage

General Description

2-Amino-4-chloro-6-cyclopropylpyrimidine is a chemical compound with the molecular formula C7H7ClN4. It is a pyrimidine derivative with a cyclopropyl group and a chlorine atom attached to the 4th and 6th carbon atoms, respectively. 2-aMino-4-chloro-6-cyclopropylpyriMidine is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has been studied for its potential applications in the treatment of various diseases, including cancer and viral infections. Additionally, it may also have uses in the field of materials science and as a reagent in organic chemistry reactions. The compound's unique structure and properties make it a valuable building block in the synthesis of a wide range of important compounds.

Upstream product

• 24922-02-9 Ethyl 3-cyclopropyl-3-oxopropionate 
• 21573-08-0 2-amino-6-cyclopropylpyrimidin-4-ol 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 

Relevant articles and documents

SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS

The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5', R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.

Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H 4 receptor antagonists

This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. Building on our SAR studies of saturated derivatives from the indole carboxamide series, typified by JNJ 7777120, and incorporating knowledge from the tricyclic pyrimidines led us to the 6-alkyl-2,4-diaminopyrimidine series. A focused medicinal chemistry effort delivered several 6-alkyl-2,4-diaminopyrimidines that behaved as antagonists at both the human and rodent H4 receptor. Further optimization led to a panel of antagonists that were profiled in animal models of inflammatory disease. On the basis of the preclinical profile and efficacy in several animal models, JNJ 39758979 was selected as a clinical candidate; however, further development was halted during phase II because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.

ARYL PYRIMIDINE DERIVATIVES AND USES THEREOF

The aryl pyrimidine derivatives and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, including utility as selective 5HT 2B-antagonists. The 5-HT 2B antagonist is a compound of the formula: STR1 wherein: R. sup.1 is hydrogen, alkyl, lower alkoxy, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl,--NR 6 R. sup.7,--CO 2 R 8,--O(CH 2) n R 9, or lower alkyl optionally substituted with hydroxy, alkoxy, halo, or aryl; in which n is 1, 2, or 3;R 6 and R 7 are hydrogen or lower alkyl; R 8 is hydrogen or lower alkyl; andR 9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;R. sup.2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl; R 3 is optionally substituted aryl other than pyridyl, thienyl, or furanyl;R 4 is hydrogen, lower alkyl, cycloalkyl, alkenyl, acyl, amino, amido, aryl,--(CH 2) m NR. sup.10 R 11, or lower alkyl optionally substituted by amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, aryl, lower alkoxy, amido, alkoxy carbonyl, tetrahydrofuran-2-yl, hydroxyalkoxy, or sulfonamido;in whichR 10 and R. sup.11 are hydrogen or lower alkyl; andR 5 is hydrogen or lower alkyl; provided that: (i) when R 3 is naphthyl, indol-1-yl, or 2,3-dihydroindol-1-yl, and R 2, R 4 and R 5 are all hydrogen, R. sup.1 is not methyl; (ii) when R 3 is phenyl or naphthyl, R 1 is not--NR 6 R 7 ;(iii) when R 3 is phenyl, R 2 is not lower alkoxy, and R 1 and R 2 are not halo;(iv) when R 3 is phenyl and R 1 is H, R 2 is not methyl; and (v) when R 3 is 1,2,3,4-tetrahydroquinolinyl, R 4 and R. sup.5 are hydrogen;or a pharmaceutically acceptable salt or N-oxide thereof.